ANEB-001 / Anebulo Pharma - LARVOL DELTA

CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial. (PubMed, Clin Pharmacol Ther) - "Nausea and vomiting occurred more frequently at high selonabant doses; 10-mg selonabant was both well tolerated and efficacious. Present results support further development of selonabant for emergency treatment of ACI."

Clinical • Journal • P2 data • Cardiovascular • CNS Disorders • Mood Disorders • Psychiatry

Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults (ACEP 2023) - No abstract available

Clinical

Prediction of a Therapeutically Active Dose of the Cannabinoid Type 1 Receptor Antagonist ANEB-001 For Reversal of Acute Cannabis Intoxication Using a Pharmacokinetic/Pharmacodynamic Model (ACEP 2023) - No abstract available

PK/PD data

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test (clinicaltrials.gov) - P2 | N=154 | Completed | Sponsor: Anebulo Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Model (clinicaltrials.gov) - P2 | N=134 | Active, not recruiting | Sponsor: Anebulo Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Enrollment closed • Trial completion date • Trial primary completion date

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Model (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Anebulo Pharmaceuticals | N=60 ➔ 150

Enrollment change

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Model (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Anebulo Pharmaceuticals

New P2 trial